Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.81 |
| ▸ | NPC1 | O15118 | 9/20 | 0.81 |
| ▸ | RAB9A | P51151 | 9/20 | 0.81 |
| ▸ | GAA | P10253 | 7/20 | 0.81 |
| ▸ | NFKB1 | P19838 | 6/20 | 0.81 |
| ▸ | NFKB2 | Q00653 | 6/20 | 0.81 |
| ▸ | RELA | Q04206 | 6/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.81 |
| ▸ | MEN1 | O00255 | 4/20 | 0.81 |
| ▸ | POLB | P06746 | 4/20 | 0.81 |
| ▸ | GFER | P55789 | 2/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.76 |
| ▸ | HPGD | P15428 | 5/20 | 0.76 |
| ▸ | GLA | P06280 | 4/20 | 0.76 |
| ▸ | PKM | P14618 | 3/20 | 0.76 |
| ▸ | APP | P05067 | 7/20 | 0.65 |
| ▸ | MMP9 | P14780 | 1/20 | 0.65 |
| ▸ | MMP8 | P22894 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29918176 | 0.89 | MAPT (1.00) | MAPTKDM4ENPC1RAB9AGAA | |
| SCHEMBL6399498 | 0.89 | MAPT (1.00) | MAPTKDM4ENPC1RAB9AGAA | |
| SCHEMBL6401979 | 0.88 | MAPT (0.77) | MAPTKDM4ENPC1RAB9AGAA | |
| SCHEMBL3194266 | 0.86 | MAPT (1.00) | MAPTKDM4ENPC1RAB9AGAA | |
| SCHEMBL19148568 | 0.83 | MAPT (0.81) | MAPTKDM4ENPC1RAB9AGAA | |
| SCHEMBL2242138 | 0.83 | MAPT (0.82) | MAPTKDM4ENPC1RAB9AGAA | |
| SCHEMBL2244906 | 0.83 | MAPT (0.81) | MAPTKDM4ENPC1RAB9AGAA | |
| SCHEMBL13650109 | 0.83 | MAPT (0.69) | MAPTKDM4ENPC1RAB9AGAA | |
| SCHEMBL19149498 | 0.83 | KDM4E (0.65) | MAPTKDM4ENPC1RAB9AGAA | |
| SCHEMBL11778341 | 0.83 | NPC1 (0.66) | MAPTKDM4ENPC1RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | claimed |
| US-12413729-B2 | Chroma quantization parameter adjustment in video encoding and decoding | INTERDIGITAL VC HOLDINGS, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| CN-120129535-A | Tissue factor antibody-drug conjugates and uses thereof | 埃克塞里艾克西斯公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-119152271-A | Decoupling consistency regularization-based countermeasure training method and image classification method | 中国人民解放军国防科技大学 | 2024-12-17 | — | — | CN | disclosed |
| EP-4422679-A1 | IMMUNOGENIC FUSION PROTEINS AGAINST CORONAVIRUS | Navicure Biopharmaceuticals Limited (WS) | 2024-09-04 | — | — | EP | disclosed |
| WO-2024081996-A1 | METHOD OF TREATING SEVERE ASTHMA | CSL Innovation Pty Ltd (AU) | 2024-04-25 | — | — | WO | disclosed |
| US-20240089437-A1 | CHROMA QUANTIZATION PARAMETER ADJUSTMENT IN VIDEO ENCODING AND DECODING | INTERDIGITAL VC HOLDINGS, INC. (US) | 2024-03-14 | — | — | US | disclosed |
| CN-113195530-B | Antibody fusion protein, preparation method and application thereof | 长春金赛药业有限责任公司 | 2023-06-16 | — | — | CN | disclosed |
| CN-112961250-B | Antibody fusion proteins and uses thereof | 长春金赛药业有限责任公司 | 2023-06-06 | — | — | CN | disclosed |
| WO-2023076820-A1 | IMMUNOGENIC FUSION PROTEINS AGAINST CORONAVIRUS | NAVICURE BIOPHARMACEUTICALS LIMITED (WS) | 2023-05-04 | — | — | WO | disclosed |
| EP-2170396-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BioMarin IGA Limited (BS) | 2010-04-07 | — | — | EP | disclosed |
| US-7674809-B2 | Anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | ROTTAPHARM S.P.A. (IT) | 2010-03-09 | — | — | US | disclosed |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT (OXFORD) LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| WO-2009019504-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-02-12 | — | — | WO | disclosed |
| EP-1986633-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007091106-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
| US-20050197331-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | ROTTAPHARM SPA | 2005-09-08 | — | — | US | disclosed |
| EP-1571142-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | Rottapharm S.p.A. (IT) | 2005-09-07 | — | — | EP | disclosed |
| CN-1026322-C | Process for preparing benzodumb azole derivatives | TANABE SEIYAKU CO (JP) | 1994-10-26 | — | — | CN | disclosed |
| CN-88101542-A | Benzoxazole derivatives and process for preparing them | — | 1988-10-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | PYGM, CPT1B, GYS1 | MAPT 3113/4885KDM4E 3311/4885NPC1 2477/4885 |
| US-20050197331-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | NOS3, NOS1, NOS2 | MAPT 4542/4885KDM4E 3052/4885NPC1 4082/4885 |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | MAPT 4858/4885KDM4E 2080/4885NPC1 3637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.